140 related articles for article (PubMed ID: 37880020)
1. Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
Nukaya T; Takahara K; Yoshizawa A; Saruta M; Yano Y; Ohno T; Uchimoto T; Fukuokaya W; Adachi T; Yamazaki S; Tokushige S; Nishimura K; Tsujino T; Nakamori K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Hirasawa Y; Hashimoto T; Komura K; Inamoto T; Miki J; Kimura T; Ohno Y; Azuma H; Shiroki R
Clin Genitourin Cancer; 2024 Feb; 22(1):76-83. PubMed ID: 37880020
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Ikeda T; Ishihara H; Nemoto Y; Tachibana H; Fukuda H; Yoshida K; Takagi T; Iizuka J; Hashimoto Y; Ishida H; Kondo T; Tanabe K
Urol Oncol; 2021 Oct; 39(10):735.e9-735.e16. PubMed ID: 34172370
[TBL] [Abstract][Full Text] [Related]
3. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
Kato T; Fujita K; Minami T; Nagahara A; Hyashi Y; Nakata W; Matsuzaki K; Nakano K; Hatano K; Kawashima A; Imamura R; Takada S; Nishimura K; Tsujihata M; Takao T; Nakai Y; Nakayama M; Nishimura K; Uemura M; Uemura H; Nonomura N
Int J Clin Oncol; 2022 Oct; 27(10):1596-1604. PubMed ID: 35831538
[TBL] [Abstract][Full Text] [Related]
4. Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis.
Washino S; Shirotake S; Takeshita H; Inoue M; Miura Y; Hyodo Y; Kagawa M; Izumi K; Oyama M; Kawakami S; Saito K; Matsuoka Y; Taniuchi S; Shintani A; Miyagawa T
Int J Clin Oncol; 2023 Dec; 28(12):1651-1658. PubMed ID: 37658926
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
Ishihara H; Nemoto Y; Nakamura K; Ikeda T; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Takagi T; Ishida H; Kondo T; Tanabe K
Target Oncol; 2021 Jul; 16(4):493-502. PubMed ID: 34173936
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214
[TBL] [Abstract][Full Text] [Related]
7. Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma.
Hara T; Furukawa J; Shiraishi Y; Okamura Y; Bando Y; Terakawa T; Harada K; Nakano Y; Fujisawa M
Int J Urol; 2023 Sep; 30(9):746-752. PubMed ID: 37130778
[TBL] [Abstract][Full Text] [Related]
8. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab.
Ishihara H; Takagi T; Kondo T; Homma C; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Urol Oncol; 2019 Jun; 37(6):355.e21-355.e29. PubMed ID: 30935847
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study.
Tanaka T; Hatakeyama S; Numakura K; Kido K; Noro D; Oikawa M; Hosogoe S; Tokui N; Yamamoto H; Narita S; Ito H; Yoneyama T; Hashimoto Y; Kawaguchi T; Habuchi T; Ohyama C
Int J Urol; 2020 Dec; 27(12):1095-1100. PubMed ID: 32893401
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab.
Ueda K; Suekane S; Kurose H; Ito N; Ogasawara N; Hiroshige T; Chikui K; Ejima K; Uemura K; Nakiri M; Nishihara K; Igawa T
Jpn J Clin Oncol; 2022 May; 52(5):479-485. PubMed ID: 35141749
[TBL] [Abstract][Full Text] [Related]
11. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients.
Kankkunen E; Penttilä P; Peltola K; Bono P
Acta Oncol; 2022 Oct; 61(10):1240-1247. PubMed ID: 35905053
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
[TBL] [Abstract][Full Text] [Related]
13. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
van Not OJ; Verheijden RJ; van den Eertwegh AJM; Haanen JBAG; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kamphuis AM; Kapiteijn E; May AM; de Meza MM; Piersma D; van Rijn R; Stevense-den Boer MA; van der Veldt AAM; Vreugdenhil G; Blokx WAM; Wouters MJM; Suijkerbuijk KPM
JAMA Oncol; 2022 Dec; 8(12):1794-1801. PubMed ID: 36301521
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Hammers HJ; Plimack ER; Infante JR; Rini BI; McDermott DF; Lewis LD; Voss MH; Sharma P; Pal SK; Razak ARA; Kollmannsberger C; Heng DYC; Spratlin J; McHenry MB; Amin A
J Clin Oncol; 2017 Dec; 35(34):3851-3858. PubMed ID: 28678668
[TBL] [Abstract][Full Text] [Related]
15. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
16. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
17. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Tasaki Y; Hamamoto S; Sugiyama Y; Tomiyama N; Naiki T; Etani T; Taguchi K; Matsuyama N; Sue Y; Mimura Y; Kubota H; Noda Y; Aoki M; Moritoki Y; Nozaki S; Kurokawa S; Okada A; Kawai N; Yasui T; Kimura K
Int J Urol; 2023 Oct; 30(10):866-874. PubMed ID: 37278575
[TBL] [Abstract][Full Text] [Related]
18. Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma.
Tomiyama N; Tasaki Y; Hamamoto S; Sugiyama Y; Naiki T; Etani T; Taguchi K; Matsuyama N; Sue Y; Mimura Y; Odagiri K; Noda Y; Aoki M; Moritoki Y; Nozaki S; Kurokawa S; Okada A; Kawai N; Furukawa-Hibi Y; Yasui T
Int J Urol; 2023 Sep; 30(9):754-761. PubMed ID: 37150513
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract][Full Text] [Related]
20. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program.
Verzoni E; Cartenì G; Cortesi E; Giannarelli D; De Giglio A; Sabbatini R; Buti S; Rossetti S; Cognetti F; Rastelli F; Sobrero A; Turci D; Sternberg CN; Porta C; Cappuzzo F; Tortora G; Tassinari D; Panni S; Pazzola A; Surico G; Raimondi A; De Giorgi U; Procopio G;
J Immunother Cancer; 2019 Apr; 7(1):99. PubMed ID: 30944023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
